Graphpad plasma serial dilution8/29/2023 In order to apply SARS-CoV-2 serologic testing strategies to inform public health interventions and individual patient management, serologic correlates of protection against SARS-CoV-2, in terms of antibody type and concentration, and duration of immunity conferred must be clearly established. Since April 2020, serologic assays to detect antibodies produced against SARS-CoV-2 have become widely available in the United States. Recently, the FDA issued EUAs for rapid testing platforms that detect viral antigens. The overwhelming majority of these FDA-authorized assays are nucleic acid amplification tests in the form of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays for testing respiratory specimens (nasal and nasopharyngeal swabs). Since the start of the pandemic, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for nearly 200 assays to support the COVID-19 response in the United States. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification tests, antigen-based tests, and serologic assays have been developed and used extensively worldwide for diagnostic, screening, and surveillance purposes. Immunity, pandemic, quantitative assays, SARS-CoV-2, serology
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |